Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Other Non-Current Liabilities: 2020-2025

Historic Other Non-Current Liabilities for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to $3.3 million.

  • Apellis Pharmaceuticals' Other Non-Current Liabilities fell 66.86% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 million, marking a year-over-year decrease of 66.86%. This contributed to the annual value of $8.0 million for FY2024, which is 244.81% up from last year.
  • According to the latest figures from Q3 2025, Apellis Pharmaceuticals' Other Non-Current Liabilities is $3.3 million, which was up 56.74% from $2.1 million recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Other Non-Current Liabilities registered a high of $345.2 million during Q4 2021, and its lowest value of $347,000 during Q1 2023.
  • In the last 3 years, Apellis Pharmaceuticals' Other Non-Current Liabilities had a median value of $2.3 million in 2023 and averaged $3.1 million.
  • Per our database at Business Quant, Apellis Pharmaceuticals' Other Non-Current Liabilities tumbled by 99.55% in 2022 and then spiked by 939.01% in 2024.
  • Quarterly analysis of 5 years shows Apellis Pharmaceuticals' Other Non-Current Liabilities stood at $345.2 million in 2021, then tumbled by 99.31% to $1.9 million in 2022, then slumped by 51.19% to $2.3 million in 2023, then skyrocketed by 244.81% to $8.0 million in 2024, then slumped by 66.86% to $3.3 million in 2025.
  • Its Other Non-Current Liabilities was $3.3 million in Q3 2025, compared to $2.1 million in Q2 2025 and $2.1 million in Q1 2025.